Advanced and Targeted Drug Delivery Market Segmentation, Analysis & Forecast to 2021Nanoparticles, Polymers, Liposomes, Micelles, Nanoemulsions, Dendrimers, Monoclonal Antibodies by Geography, Therapeutic Area and Stakeholder Environment

1.0 INTRODUCTION

1.1 Executive Summary
1.2 About this Report
1.3 Key Questions Answered in this Report

2.0 TARGETED DRUG DELIVERY: AN OVERVIEW

2.1 The Need for Targeted Delivery
2.2 Advantages and Disadvantages of Targeted Drug Delivery
2.3 Types of Drug Targeting
  2.3.1 Active Targeting
  2.3.2 Passive Targeting
    2.3.2.1 Passively Targeted Therapeutic Preparations
    2.3.2.2 Polymeric Nanoparticles (NPs) Developed for Passive Delivery of Drugs
2.4 Ideal Characteristics of Targeted Drug Delivery Carriers
2.5 Drug Carriers used in Targeting Systems

3.0 TARGETED DRUG DELIVERY AND NANOMEDICINES: AN OVERVIEW

3.1 Ideal Characteristics of Nanoparticles suited for Targeted Delivery
3.2 Size of Therapeutic Nanoconstructs
3.3 Examples of Nanomedicines Approved by One or More Regulatory Bodies
  3.3.1 Brief Description of Approved Nanomedicines
    3.3.1.1 Doxil
    3.3.1.2 Myocet
    3.3.1.3 DaunoXome
    3.3.1.4 ThermoDox
    3.3.1.5 Abraxane
    3.3.1.6 Rexin-G
    3.3.1.7 Oncaspar
    3.3.1.8 Resovist
    3.3.1.9 Feridex
    3.3.1.10 Marquibo
    3.3.1.11 Brentuximab Vedotin (Adectris)
    3.3.1.12 Trastuzumab Emtansine (Kadcyla)
  3.3.2 Therapeutic Nanomedicines in Clinical Trials
3.4 Targeting Approaches of Nanomedicines
  3.4.1 Targets of Nanomedicines in the Body
  3.4.2 Targeting Ligands
3.5 Mechanism of Internalization of Nanomedicine
3.6 Future Direction of Nanomedicines
3.7 Examples of Nanomedicine Applications
3.8 Rationale for Nanomedicine Approach
3.9 Commercially Available Oral Nanotherapeutics
3.10 Commercially Available Nanotherapeutics for Parenteral Administration
3.11 Examples of FDA-Approved Nanomedicines for Intravenous Route of Administration
3.12 Examples of FDA-Approved Nanomedicines for Pulmonary Route of Administration
3.13 Examples of FDA-Approved Nanomedicines for Subcutaneous, Intramuscular, Transdermal and Ocular Route of Administration
3.14 Examples of Nano-Based Medical Devices and Diagnostics
3.15 Various Types of Nanocarriers Expoited in Formulating Nanomedicines
  3.15.1 Types of Nanoparticles
3.16 Use of Nanoparticles in Different Fields of Medicine
  3.16.1 Nanosystems for Cancer Treatment
  3.16.2 Use of Nanosystems in Tissue Engineering
  3.16.3 Use of Nanoparticles (NPs) in Stem Cell Therapy
  3.16.4 Use of Nanoparticles in Contrast Agents
3.17 Segmentation of Targeted Drug Delivery Nanosystems

4.0 LIPID-BASED TARGETED DRUG DELIVERY NANOSYSTEMS

4.1 Advantages and Disadvantages of Liposomes as Targeted Drug Delivery Systems
4.2 Classification of Liposomes on the Basis of Size and Composition
  4.2.1 Classification of Liposomes on the Basis of Method of Preparation
4.3 Size of Liposomes
4.4 New Generation of Liposomes and their Features
4.5 Conventional Liposomes
  4.5.1 Benefits of Drug Loads in Liposomes
  4.5.2 Loading Liposomes with Drugs
  4.5.3 Intracellular Delivery of Drugs by Liposomes
  4.5.4 Liposome-Based Drugs in the Market
  4.5.5 Liposome-Based Drugs for Cancer Therapy
  4.5.6 Liposomal Drugs in Clinical Trial
4.6 Modified Liposomes
  4.6.1 Stealth Liposomes
    4.6.1.1 Approved Stealth Liposomes
4.7 Targeted Liposomes
  4.7.1 Stimuli-Sensitive Targeted Liposomes
  4.7.2 Targeted Liposomal Drugs for Cancer
4.8 Technology Developments in Lipid-Based Carriers
4.9 Key Players Focusing on Lipid-Based Carriers

5.0 POLYMER-BASED CARRIERS FOR TARGETED DRUG DELIVERY

5.1 Stimuli-Responsive or Smart Polymers
  5.1.1 Temperature-Responsive Polymers
    5.1.1.1 Classification of Thermosensitive Polymers
  5.1.2 PH-Sensitive Polymers
  5.1.3 Bioresponsive Polymers
  5.1.4 Field-Responsive Polymers
5.2 Polymer-Based Topical Delivery Systems for Dermatological Diseases
  5.2.1 Natural Polymer-Based Topical Delivery Systems
  5.2.2 Topical Delivery Systems Based on Synthetic Polymeric Particles
5.3 Clinical Status of Polymeric Nanoparticles in Cancer Treatment
5.4 Polymeric Nanoparticle-Based Therapeutics in Clinical Trials
5.5 Key Players Focusing on Polymer-Based Carriers

6.0 POLYMERIC MICELLE/CO-POLYMERS FOR TARGETED DRUG DELIVERY

6.1 Substances used to produce Micelle and their Drug Release Duration
6.2 Existing Approaches to Achieve Sustained Release from Micelle
  6.2.1 Stimulai-Responsive Micelles
6.3 Passive Targeting of Polymeric Micelle
6.4 Active Targeting of Polymeric Micelle
6.5 Stimuli-Responsive Polymeric Micelles
6.6 Multifunctional Polymeric Micelles
  6.6.1 Examples of Multifunctional Drug-Loaded Micelle
  6.6.2 Multifunctional Micelles for the Delivery of siRNA
6.7 Drug-Loaded Polymeric Micelle-Based Products in Development

7.0 DENDRIMER-BASED TARGETED DRUG DELIVERY

7.1 Three-Dimensional Structure of Dendrimers
7.2 Dendrions as Multifunctional Nanoplatforms
7.3 Commercially Available and Late-Stage Dendrimers
7.4 Therapeutic Moieties studied using Dendrimer Platform
7.5 Thermosensitive Dendrimers

8.0 INORGANIC NANOPARTICLES FOR TARGETED DRUG DELIVERY

8.1 Companies Focusing on Inorganic Nanoparticles
8.2 Carbon-Based Nanoparticles for Drug Delivery
  8.2.1 Carbon Nanotubes (CNTs)
    8.2.1.1 Structure of Carbon Nanotubes
    8.2.1.2 Artificial Implants from Carbon Nanotubes (CNTs)
    8.2.1.3 Detection of Cancer Biomarker by Carbon Nanotubes
    8.2.1.4 Drug and Gene Delivery by Carbon Nanotubes
8.3 Fullerenes
  8.3.1 Structure of Fullerene
  8.3.2 Biomedical Applications of Fullerenes
8.4 Graphine Oxide (GO) as Nanocarriers
  8.4.1 GO for Drug Delivery
8.5 Gold-Based Nanoparticles (AuNPs)
  8.5.1 Shapes of Gold Nanoparticles
  8.5.2 Imaging Applications of Gold Nanoparticles
  8.5.3 Drug Delivery Applications of Gold Nanoparticles
  8.5.4 Diagnostic Applications of Gold Nanoparticles
8.6 Silica Nanoparticles for Drug Delivery
  8.6.1 Types of Silica Nanoparticles
  8.6.2 The Process of Synthesis of SNs
  8.6.3 Drugs Delivered through Silica Nanoparticles
8.7 Magnetic Particles for Drug Delivery
  8.7.1 Companies Focusing on Magnetic Particles
  8.7.2 Typical Design of a Magnetic Nanoparticle
  8.7.3 Use of Magnetic Nanoparticles
  8.7.4 Diagnostic Use
  8.7.5 Coating Materials for Magnetic Nanoparticles
  8.7.6 Organic Linkers in Magnetic Nanoparticles
  8.7.7 Targeted Magnetic Nanoparticles (MNPs) as Cancer Theranostics
  8.7.8 Targeting Magnetic Nanoparticles to Tumors (Passive and Active)
  8.7.9 Magnetic Nanoparticles as Diagnostics
  8.7.10 Magnetic Nanoparticles as Multimodal Imaging Agents
  8.7.11 FDA/EMEA Approved Magnetic Nanoparticle-Based Cotrast Agents

9.0 CELL-BASED SYSTEMS FOR TARGETED DELIVERY

9.1 Companies Focusing on Cell-Based Carriers
9.2 Role of Dendritic Cells (DCs) in Drug Delivery
9.3 Engineered RBCs for Drug Delvery
  9.3.1 Therapeutic Sites and Targets Accessible for RBC-Delivered Drugs
  9.3.2 Examples of Therapeutic Enzymes Encapsulated in Carrier RBCs
9.4 Stem Cells for Drug Delivery
9.5 Bacterial Ghosts for Drug Delivery

10.0 NUCLEIC ACID/PEPTIDE AS DRUG CARRIERS

10.1 `Companies Focusing on Aptamers/Nucleic Acids/Peptides
10.2 Peptide Conjugates for Drug Delivery
  10.2.1 Peptides as Radfionuclide Carriers
  10.2.3 Peptide Hormones
  10.2.4 Peptide Vaccines
  10.2.5 Peptide as Cytotoxic Drug Carrier
  10.2.6 Cell-Penetrating Peptides
  10.2.7 Peptides Applied in Cancer Diagnostics
  10.2.8 Peptides Applied in Treating Cancer
  10.2.9 Peptide-Based Vaccines in Clinical Development
10.3 DNA/RNA Aptamers
  10.3.1 Clinical Use of Aptamers
10.4 DNA Origami (DNA Nanorobots)

11.0 TARGETED THERAPIES BY INDICATION: AN OVERVIEW

11.1 Targeted Cancer Therapies
  11.1.1 Identification of Targets in Cancer Therapy
  11.1.2 Categories and Examples of Tumor Antigens
  11.1.3 Development of Targeted Therapies for Cancer
  11.1.4 Targeted Cancer Therapies in Late Stage Development
  11.1.5 Companies Focusing on Oncology Applications of Targeted Drug Delivery
11.2 Monoclonal Antibodies (mAbs) and Targeted Drug Delivery
  11.2.1 Monoclonal Antibodies (mAbs)
    11.2.1.1 Naked mAbs
    11.2.1.2 Examples of Naked mAbs and their Fuctions
    11.2.1.3 Conjugated mAbs
    11.2.1.4 Bispecific mAbs
  11.2.2 U.S./E.U.-Approved mAbs
  11.2.3 mAbs by Indication Area
  11.2.4 mAb Biosimilars in Late Stage Development
  11.2.5 Biosimilar mAbs in Development
11.3 Ocular Applications of Targeted Drug Delivery
  11.3.1 Ocular Applications of Dendrimer Systems
  11.3.2 Ocular Applications of Liposomes
  11.3.3 Micelles in Ocular Drug Delivery
    11.3.3.1 Micelle Systems Investigated for Ocular Drug Delivery
  11.3.4 Viral and Non-Viral Vectors for Ocular Gene Delivery
11.4 Targeted Drug Delivery for Central Nervous System (CNS) Disorders
  11.4.1 Blood Brain Barrier (BBB)
  11.4.2 Drug Delivery Approaches and Drug Molecules for Brain
  11.4.3 Examples of Nanoparticles (NPs) used for Delivery of Drugs across BBB
  11.4.4 Examples of Clinically-Approved NPs Therapeutics for CNS Disorders
  11.4.5 Dendrimers for CNS Drug Delivery
11.5 Infectious Disease Applications for Targeted Drug Delivery
  11.5.1 Liposomes for Antimicrobial Drug Delivery
  11.5.2 Polymeric Nanoparticles for Antimicrobial Drug Delivery
  11.5.3 Solid Lipid Nanoparticles (SLNs) for Antimicrobial Drug Delivery
  11.5.4 Dendrimers for Antimicrobial Drug Delivery
11.6 Cardiovascular Applications for Targeted Drug Delivery
  11.6.1 Nanoparticles for Advanced Diagnostics and Therapy of Cardiovascular Diseases
  11.6.2 Therapeutic and Theranostic Nanoparticles for CVD
  11.6.3 In vivo Nanosensors for CVD
11.7 Targeted Drug Delivery for Pulmonary Diseases
  11.7.1 Drugs for Inhalation
  11.7.2 Polymers for Colloidal Pulmonary Drug Delivery Systems
  11.7.3 Nebulizers with Novel Technologies for Pulmonary Drug Delivery
  11.7.4 Novel Dry Powder Inhalers (DPIs)
  11.7.5 Types of Nanoparticles used to Encapsulate API Molecules
11.8 Cosmeceutical Applications of Nano-Based Drugs for Targeted Delivery

12.0 OTHER TARGETED DRUG DELIVERY TECHNOLOGIES

12.1 Ocular Implants
  12.1.1 Ocular Implants under Clinical Development
  12.1.2 FDA-Approved Ocular Drug Delivery Implants
  12.1.3 Sustained Trans-Scleral Ocular Drug Delivery
12.2 Drug Eluting Stents (DES) and Targeted Drug Delivery
  12.2.1 Polymers for Stent Coatings
12.3 Microchips: The Novel Implantable Drug Delivery Technology

13.0 MARKET ANALYSIS TO 2021

13.1 Applications of Nanoparticles in Healthcare
13.2 Types of Nanomedicine Companies
13.3 Global Market for Nanomedicines to 2021
  13.3.1 Nanomedicines Market by Major Therapeutic Area
13.4 Global Market for Targeted Drug Delivery to 2021
  13.4.1 Global Market for mAbs to 2021
    13.4.1.1 Best-Selling mAbs 2014-2021
    13.4.1.2 Global Market for Humira, Remicade and Avastin
    13.4.1.3 Global Market for Rituxan, Soliris and Herceptin
    13.4.1.4 Global Market for Kadcyla, Perjeta and Lucentis
    13.4.1.5 Global Market for Xgeva/Prolia, Stelara and Tysarbi
13.5 Global Market for Nanoparticle-Based Targeted Drug Delivery Systems to 2021
13.6 Ocular Drug Delivery Market to 2021
  13.6.1 Novel Ocular Drug Delivery Systems
    13.6.1.2 Ocular Drug Delivery Implants
13.7 Global Market for Implanted Drug Eluting Stents to 2021
13.8 Pulmonary Drug Delivery to 2021
13.9 What does the Future hold for the Targeted Drug Delivery Market?
13.10 Impact of New Technology Systems on the Current Targeted Delivery Market
13.11 Future Directions in Drug Delivery
13.12 Disruptive Technologies within the Existing Targeted Delivery Market
  13.12.1 Emergence of Hydrogels in Oral Drug Delivery
  13.12.2 Emergence of PEGylated Phospholipid Nanocarriers for Respiratory Diseases
  13.12.3 Emergence of Cyclodextrins
    13.12.3.1 Cyclodextrins in Oral Drug Delivery
    13.12.3.2 Cyclodextrins in Rectal Drug Delivery
    13.12.3.3 Cyclodextrin in Nasal Drug Delivery
    13.12.3.4 Cyclodextrins in Transdermal Drug Delivery
    13.12.3.5 Cyclodextrins in Ocular Drug Delivery
    13.12.3.6 Cyclodextrins in Controlled Drug Delivery

14.0 SELECTED COMPANY PROFILES

14.1 3M Company
  14.1.1 3M Drug Delivery Systems
14.2 Abbott Laboratories
  14.2.1 Gengraf
  14.2.2 Kaletra
  14.2.3 Norvir
14.3 Ablynx NV
  14.3.1 Nanobody Technology
  14.3.2 Clinical Programs
  14.3.3 Ablynx’s Partnership with Boehringer Ingelheim
  14.3.4 Ablynx’s Partnership with Eddingpharm
  14.3.5 Ablynx’s Partnership with Genzyme
  14.3.6 Ablynx’s Partnership with Merck & Co.
  14.3.7 Ablynx’s Partnership with Merck KGaA
  14.3.8 Ablynx’s Partnership with Novartis
  14.3.9 Ablynx’s Partnership with Taisho Pharmaceutical
14.4 Aciont Inc.
  14.4.1 Visulex Technology
14.5 Acrux
  14.5.1 Patchless Patch
  14.5.2 Axiron
  14.5.3 Evamist & Lenzetto
14.6 Agilis Biotherapeutics LLC
  14.6.1 Agilis’ Engineered DNA Therapeutics
  14.6.2 Agilis’ DNA Therapeutic Programs
    14.6.2.1 DNA Therapeutics for Friedreich’s Ataxia
    14.6.2.2 DNA Therapeutics for Angelman Syndrome (AS)
14.7 Aileron Therapeutics Inc.
  14.7.1 P53 Pathway Re-Activator
14.8 Alchemia Oncology Pty Ltd.
  14.8.1 HA-Irinotecan
  14.8.2 HA-Doxorubicin (Hyaluronic acid + Doxorubicin)
  14.8.3 HA-5-Fluorouracil (Hyaluronic acid + 5-Fluorouracil)
  14.8.4 Monoclonal Antibodies
14.9 Alkermes Pharma Ireland Ltd.
  14.9.1 Aristada
  14.9.2 Vivitrol
  14.9.3 U.S. Products using Alkermes’ Technologies
    14.9.3.1 Bydureon
    14.9.3.2 Ampyra
    14.9.3.3 Risperdal Consta
    14.9.3.4 Invega Trinza
  14.9.4 Alkermes’ Long-Acting Technologies
    14.9.4.1 Medisorb Technology
    14.9.4.2 LinkeRx Technology
    14.9.4.3 NanoCrystal Technology
14.10 Allergan Inc.
  14.10.1 Doryx (Delayed-Release Tablets)
  14.10.2 Saphris (Sub-Lingual Tablets)
  14.10.3 Namenda XR (Extended Release Capsules)
  14.10.4 Namzaric (Extended Release Capsule)
  14.10.5 Asacol HD (Delayed-Release Tablets)
  14.10.6 Delzicol (Delayed-Release Tablets)
  14.10.7 Zenpep (Delayed-Release Tablets)
14.11 Alnylam Pharmaceuticals
  14.11.1 Development Pipeline
  14.11.2 Strategic Alliances
14.12 AmpliPhi Biosciences
  14.12.1 Product Pipeline
14.13 Andros Pharmaceuticals Co., Ltd.
  14.13.1 High-End Cosmetic Ingredient
  14.13.2 Topical Drug Delivery System
  14.13.3 Gene Delivery System
14.14 Angiochem Inc.
  14.14.1 LRP-1 Technology
14.15 Antares Pharma Inc.
  14.15.1 VIBEX
  14.15.2 Pen Injectors
  14.15.3 Partnered Products
14.16 Aposense Ltd.
  14.16.1 Apo-si
  14.16.2 ATT-11T
  14.16.3 F-ML-10
  14.16.4 ATT-LD
14.17 Applied Genetic Technologies Corp. (AGTC)
  14.17.6 Technology
14.18 Aptagen LLC
  14.18.1 Apta-Services (R&D Support)
  14.18.2 Apta-Index
14.19 Aradigm Corp.
  14.19.1 Technology
  14.19.2 Aradigm’s Product Pipeline
14.20 ArisGen SA
  14.20.1 ArisCrown Technology
  14.20.2 Sublingual Exenatide ARG011
14.21 Armagen Technologies Inc.
  14.21.1 Armagen’s Technology
  14.21.2 Armagen’s Licensing and Collaboration Agreement with Shire
  14.21.3 Armagen’s Partnership with PacificGMP
14.22 Arrowhead Research Corp.
  14.22.1 Arrowhead’s Lead Products
  14.22.2 The Dynamic Polyconjugate Platform
14.23 Artificial Cell Technologies Inc.
  14.23.1 Technology
  14.23.2 Respiratory Syncytial Virus (RSV) Vaccine
  14.23.3 Malaria Vaccine
14.24 AsclepiX Therapeutics LLC
  14.24.1 Anti-Angiogenesis Therapy
14.25 Asklepios BioPharmaceutical Inc.
  14.25.1 Asklepios’ Collaboration with Baxter
  14.25.2 Asklepios’ Collaboration with Medtronic
  14.25.3 Asklepios’ Collaboration with ALS Therapy Development Institute
  14.25.4 Asklepios’ Collaboration with Genzyme
  14.25.5 Asklepios’ Collaboration with Pfizer
14.26 Astellas Pharma Inc.
  14.26.1 AmBisome
14.27 Audentes Therapeutics Inc.
  14.27.1 Technology
14.28 Avalanche Biotechnologies Inc.
  14.28.1 The Ocular BioFactory Platform
14.29 Avita Medical Ltd.
  14.29.1 ReCell FOR Burns and Plastics
  14.29.2 ReCell for pigmentation
  14.29.3 ReCell for Chronic Wounds
  14.29.4 Funhaler
  14.29.5 Breath-A-Tech
14.30 Azaya Therapeutics Inc.
  14.30.1 Products
14.31 Bachem Americas Inc.
  14.31.1 API Products
14.32 Bayer Pharma AG
14.32,1 Cipro
14.33 BBB Therapeutics BV
  14.33.1 G-Technology
  14.33.2 Product Pipeline
14.34 Bespak Europe Ltd.
  14.34.1 Inhalation Delivery Devices
  14.34.2 Injectable Drug Delivery Devices
  14.34.3 VapourSoft Technology
  14.34.4 ASI Technology
14.35 Bicycle Therapeutics Ltd.
  14.35.1 Bicycle Molecules
  14.35.2 R & D in Oncology
  14.35.3 R & D in Ophthalmology
14.36 BigDNA Ltd.
  14.36.1 Technology
14.37 BIND Therapeutics Inc.
  14.37.1 Accurins
  14.37.2 BIND Therapeutics’ Intellectual Property
  14.37.3 BIND’s Collaboration with Pfizer
  14.37.4 BIND’s Collaboration with Merck
14.38 BioDelivery Sciences International Inc.
  14.38.1 BEMA Technology
  14.38.2 Onsolis
  14.38.3 Belbuca (Buprenorphine HCL Buccal Film)
  14.38.4 Bunavail
  14.38.5 Clonidine Topical Gel
14.39 Bioject Medical Technologies Inc.
  14.39.1 Technology
  14.39.2 Biojector 2000
  14.39.3 Bioject Zetajet
  14.39.4 Biojet Drug Reconstitution System
  14.39.5 Needle-Free Vial Adapter
14.40 BioZone Laboratories Inc.
  14.40.1 QuSomes Technology
  14.40.2 LipoSpray Technology
  14.40.3 Ela-Max
14.41 Camurus AB
  14.41.1 Technologies
    14.41.1.1 FluidCrystal Injection Depot
    14.41.1.2 FluidCrystal Topical Bioadhesive
    14.41.1.3 FluidCrystal Nanoparticles
    14.41.1.4 CAM2029
    14.41.1.5 CAM2038
    14.41.1.6 CAM2038 (Chronic Pain)
    14.41.1.7 CAM2032
    14.41.1.8 Episil Oral Liquid
14.42 Celsion Corp.
  14.42.1 Celsion’s LTLD Technology
  14.42.2 Celsion’s Pipeline
14.43 CeramiSphere Pty Ltd.
  14.43.1 Technology
    14.43.1.1 Mucosal Delivery of Proteins
    14.43.1.2 Delivery of DNA and RNA
    14.43.1.3 Delivery of Wound Healing Drugs
14.44 Cerulean Pharma Inc.
  14.44.1 Nanoparticle-Drug Conjugates (NDCs)
14.45 Chrysalis BioTherapeutics Inc.
  14.45.1 Radiation Therapy (TP508)
  14.45.2 Solution for Nuclear Emergencies
  14.45.3 Solution for Cardiovascular Disease
  14.45.4 Solution for Regenerative Medicine
14.46 Copernicus Therapeutics Inc.
  14.46.1 Technology
14.47 Cornerstone Pharmaceuticals Inc.
  14.47.1 AEMD Platform
  14.47.2 Emulsiphan Pipeline
14.48 CureVac AG
  14.48.1 CureVac’s RNA Technology Platforms
14.49 CytImmune Sciences Inc.
  14.49.1 Aurimune
  14.49.2 CYT-6091
  14.49.3 CYT-21000
  14.49.4 Partnership with Coldstream Laboratories Inc.
14.50 DepoMed Inc.
  14.50.1 Acuform Technology
  14.50.2 Products
    14.50.2.1 Nucynta ER
    14.50.2.2 Cambia
    14.50.2.3 Lazanda
    14.50.2.4 Zipsor
14.51 Dicerna Pharmaceuticals
  14.51.1 DsiRNA-EX-Conjugate technology
  14.51.2 EnCore Lipid Nanoparticles
14.52 Dimension Therapeutics Inc.
  14.52.1 Engineered AAV Vectors
  14.52.2 Hemophilia Program
  14.52.3 Ornithine transcarbamylase (OTC) deficiency
  14.52.4 Glycogen Storage Disease Type Ia (GSDIa)
14.53 Dipexium Pharmaceuticals Inc.
  14.53.1 Locilex
14.54 Discovery Laboratories Inc.
  14.54.1 AEROSURF – Aerosolized KL4 Sulfactant
  14.54.2 KL4 Sulfactant
  14.54.3 Capillary Aerosol Generator (CAG) Technology
14.55 DURECT
  14.55.1 Technologies
    14.55.1.1 Epigenomic Regulator Program
    14.55.1.2 Long-Acting Injectables
    14.55.1.3 Abuse Deterrant Technology
    14.55.1.4 Transdermal Technology
  14.55.2 Patents
  14.55.3 Products in Development
    14.55.3.1 DUR-928
    14.55.3.2 POSIMIR
    14.55.3.3 REMOXY
    14.55.3.4 ORADUR
    14.55.3.5 ORADUR – Methylphenidate
    14.55.3.6 RELDAY
    14.55.3.7 ELADUR
  14.55.4 Commercial Products
    14.55.4.1 ALZET Osmotic Pumps
    14.55.4.2 LACTEL
14.56 EnGeneIC Ltd
  14.56.1 EDV Nanocells
  14.56.2 Completion of Series B Financing
  14.56.3 2015 Thomson Reuters Award
  14.56.4 EnGeneIC’s Phase I Clinical Study for Advanced Glioma Patients
14.57 Ensysce Biosciences Inc.
  14.57.1 Single-Walled Carbon Nanotubes (SWCNT)
  14.57.2 Ensysce’s Product Pipeline
14.58 EryDel SpA
  14.58.1 Technology
  14.58.2 EryDex System
14.59 EryTech Pharma
  14.59.4 ERY-ASP (GRASPA)
  14.59.5 EryTech’s Key Corporate Facts
  14.59.6 Deloitte Award
14.60 Esperance Pharmaceuticals Inc.
  14.60.1 MDPs Technology
  14.60.2 Pipeline
14.61 Exicure Inc.
  14.61.1 SNA Platform
14.62 FIT Biotech Oy
  14.62.1 Gene Transfer Unit (GTU) Platform
14.63 Flamel Technologies S.A.
  14.63.1 Flamel’s Drug Delivery Platforms
  14.63.2 Micropump
  14.63.3 LiquiTime
  14.63.4 Trigger Lock
  14.63.5 Medusa
14.64 Generex Biotechnology Corp.
  14.64.1 RapidMist Technology
  14.64.2 Antigen Express Technology
  14.64.3 Generex Oral-Lyn
14.65 Genetic Immunity Inc.
  14.65.1 DermaVir
  14.65.2 Technology
    14.64.2.1 DermaPrep
    14.64.2.2 ANTIGENeering
    14.64.2.3 Nanomedicine
14.65 Genus Pharmaceuticals Ltd.
  14.65.1 Fenogal
14.66 GenVec Inc.
  14.66.1 AdenoVerse Technology
14.67 GlaxoSmithKline LLC
  14.67.1 Adavir Diskus
  14.67.2 Sustiva
  14.67.3 Agenerase
14.68 Glide Pharmaceutical Technologies Ltd.
  14.68.1 Technologies
14.69 Heron Therapeutics Inc.
  14.69.1 Biochronomer Technology
  14.69.2 Sustol
  14.69.3 HTX-019
  14.69.4 HTX-011
14.70 Hoffmann-LaRoche Inc.
  14.70.1 Fortovase
14.71 ICB International Inc.
  14.71.1 Platform Technology
14.72 iCeutica Inc.
  14.72.1 Product Pipeline
  14.72.2 SoluMatrix Technology
14.73 ImmusanT Inc.
14.74 InDex Pharmaceuticals AB
  14.74.1 Kappaproct
14.75 Immune Design
14.76 Immunocore Ltd.
  14.76.1 ImmTACs
14.77 Inovio Pharmaceuticals
  14.77.1 SynCon Technology
14.78 Insite Vision Inc.
  14.78.1 DuraSite Technology
14.79 Insmed Inc.
14.80 Intezyne Technologies Inc.
  14.80.1 IVECT Method
  14.80.2 Intezyne’s Pipeline
14.81 Keystone Nano Inc.
  14.81.1 NanoJacket Technology
  14.81.2 NanoLiposome Technology
14.82 Kowa Pharmaceuticals America Inc.
  14.82.1 Livalo
  14.82.2 Lipofan
14.83 LipimetiX Inc.
  14.83.1 Technology
14.84 LiPlasome Pharma ApS
  14.84.1 LiPlasome’s Pipeline
  14.84.2 LiPlaCis
14.85 Lipocine Inc.
  14.85.1 LCPN 1021
  14.85.2 LCPN 1111
  14.85.3 LPCN 1107
  14.85.4 Lip’ral Technology
14.86 Lipotek Pty Ltd.
  14.86.1 Technology
14.87 Living Cell Technologies Ltd.
  14.87.1 DIABECELL
  14.87.2 NTCELL
14.88 Madison Vaccines Inc.
  14.88.1 Technology
14.89 MagForce AG
  14.89.1 NanoTherm Therapy
  14.89.2 NanoTherm
  14.89.3 NanoPlan
  14.89.4 NanoActivator
14.90 Mankind Pharma Ltd.
  14.90.1 Technosphere Technology
14.91 Mersana Therapeutics Inc.
  14.91.1 Fleximer Platform
  14.91.2 Dolaflexin
  14.91.3 Mersana’s Partnership with Takeda
  14.91.4 Mersana’s Partnership with EMD Serono
  14.91.5 Mersana’s Partnership with Recepta Biopharma S.A.
14.92 Micochips Biotech Inc.
  14.92.1 Technology
  14.92.2 Applications
  14.92.3 Current Partnerships
    14.92.3.1 Teva Pharmaceuticals
    14.92.3.2 Gates Foundation
14.93 Milo Biotechnology LLC
  14.93.1 Technology
14.94 miRagen Therapeutics Inc.
14.95 Mirna Therapeutics Inc.
  14.95.1 Technology
  14.95.2 MRX34
14.96 Miros Polymers Inc.
  14.96.1 Technology
  14.96.2 Drug Delivery Systems
    14.96.2.1 ExCell
    14.96.2.2 PolyGel
14.97 Moderna Therapeutics Inc.
  14.97.1 mRNA Expression Platform
14.98 MultiVir Inc.
  14.98.1 MultiVir’s Product Candidates
14.99 Mystic Pharmaceuticals Inc.
  14.99.1 VersiDoser Delivery Platform
  14.99.2 VRx2 Delivery Platform
  14.99.3 Intranasal Delivery Systems
  14.99.4 Nose to Brain Delivery Systems
  14.99.5 Ophthalmic Delivery Systems
  14.99.6 Sublingual Delivery Systems
14.100 Nanobiotix
  14.100.1 NanoXray
14.101 Nanocarrier Co., Ltd.
  14.101.1 Micellar Nanoparticles
14.102 Nanocopoeia Inc.
  14.102.1 ElectroNanospray (ENS) Process
14.103 NanoMedical Systems Inc.
  14.103.1 Personalized Molecular Drug Delivery System (PMDS)
  14.103.2 NanoMedical Diagnostics (NMD)
  14.103.3 Multi-Stage NanoVector Drug Delivery System (MSV)
14.104 NanoOncology Inc. (PeptiMed Inc.)
  14.104.1 NanoOncology’s Product Pipeline
  14.104.2 Ovarian Cancer Program
  14.104.3 Breast Cancer Program
  14.104.4 Lung Cancer Program
14.105 Nanospectra Biosciences Inc.
  14.105.1 AuroLase Therapy
14.106 Nano Precision Medical Inc.
  14.106.1 The NanoPortal Solution
14.107 Nanotherapeutics Inc.
14.108 nanoTherics Ltd
  14.108.1 magneTherm
  14.108.2 Live Cell Alternating Magnetic Field Exposure System (LC-AMF System)
  14.108.3 Magnefect System
14.109 NanoVector Inc.
  14.109.1 Product Strategy
  14.109.2 NVI-9010
14.110 NanoViricides Inc.
  14.110.1 Platform Technology
14.111 Nektar Therapeutics
  14.111.1 Technology
14.112 Neos Therapeutics Inc.
  14.112.1 Proprietary Technology
  14.112.2 Rapidly Disintegrating Ionic Masking
  14.112.3 Dynamic Time Release Suspension
  14.112.4 Kinetically Controlled Tamper Protection
  14.112.5 Currently Marketed Product
14.113 NeXstar Pharmaceuticals Inc.
  14.113.1 DaunoXome
14.114 NightstaRx Ltd.
  14.114.1 AAV2-REP1
14.115 NOD Pharmaceuticals Inc.
  14.115.1 Technology
    14.115.1.1 Nodlin
    14.115.1.2 Nodexen
14.116 Nordic Nanovector ASA
  14.116.1 Antibody-Radionucleotide-Cojugate
  14.116.2 Betalutin
14.117 Novagali Pharma S.A.
  14.117.1 Novasorb Technology
14.118 Novartis Pharmaceuticals Corp.
  14.118.1 Neoral
14.119 Ocular Therapeutix Inc.
  14.119.1 ReSure Sealant
  14.119.2 Dextenza
  14.119.3 Sustained Release Travoprost
  14.119.4 Posterior Segment Injections
14.120 Oncolytics Biotech Inc.
  14.120.1 Reolysin
14.121 Oxford Biomedica plc
  14.121.1 OXB-201 (RetinoStat)
  14.121.2 SAR 422459
  14.121.3 SAR 421869
  14.121.4 EncorStat
  14.121.5 OXB-102
  14.121.6 MoNuDin
  14.121.7 OXB-301 (TroVax)
  14.121.8 Anti-5T4 Antibody
  14.121.9 The LentiVector Platform
  14.121.10 5T4 Tumor Antigen
  14.121.11 CAR-T Cell Therapy
14.122 PDS Biotechnology Corp.
  14.122.1 Versamune NanoPlatform-
14.123 PharmaIN Corp.
  14.123.1 Protected Graft Copolymer (PGC)
14.124 PhaseRx Inc.
  14.124.1 mRNA Technology
14.125 Phico Therapeutics Ltd.
  14.125.1 Technology
  14.125.2 Products
    14.125.2.1 SASPject PT1.2
    14.125.2.2 SASPject PT3.1
    14.125.2.3 SASPject PT4
14.126 PolyActiva Pty Ltd.
  14.126.1 Drug Delivery Platform
  14.126.2 Glaucoma Program
  14.126.3 Endophthalmitis
  14.126.4 Osteoarthritis Program
14.127 PolyMicrospheres
14.128 PolyTherics Ltd.
  14.128.1 ThioBridge
  14.128.2 TheraPEG
  14.128.3 HiPEG
  14.128.4 CyPEG
  14.128.5 PolyPEG
14.129 Presage Biosciences Inc.
  14.129.1 CIVO Platform
14.130 pSivida Corp.
  14.130.1 Durasert Technology
  14.130.2 pSivida’s Product Pipeline
  14.130.3 Iluvien
  14.130.4 Retisert
  14.130.5 Durasert/Latanoprost
14.131 Pulmatrix Inc.
  14.131.1 iSPERSE
  14.131.2 PUR1900
  14.131.3 PUR1500
  14.131.4 PUR0200
14.132 Quark Pharmaceuticals Inc.
  14.132.1 Quark’s siRNA Technology Platform
14.133 Ra Pharmaceuticals Inc.
  14.133.1 RA101495
  13.133.2 Factor D Inhibitor
14.134 RaNA Therapeutics Inc.
14.135 RegeneRx Biopharmaceuticals Inc.
  14.135.1 T4 Peptide Research
14.136 Regenxbio Inc.
  14.136.1 NAV Technology
14.137 Renova Therapeutics Inc.
14.138 Replicor Inc.
  14.138.1 NAP Technology
  14.138.2 Replicor’s Pipeline
    14.138.2.1 Phase II Proof of Concept Clinical Study Pipeline
  14.138.3 Replicor’s Regulatory Pipeline
14.139 RetroSense Therapeutics LLC
  14.139.1 RST-001
14.140 Rexahn Pharmaceuticals Inc.
  14.140.1 Supinoxin (RX-5902)
  14.140.2 RX-3117
  14.140.3 Archexin
  14.140.4 RX-21101
  14.140.5 Archexin-Nano
14.141 RJS Biologics LLC
  14.141.1 Technology
14.142 Roche Holding AG
  14.142.1 Rocaltrol
  14.142.2 Accutane
14.143 Sarfez Pharmaceuticals Inc.
14.144 Savara Inc.
14.145 Scintipharma Inc.
  14.145.1 InteliSite Companion Capsule
14.146 Sequus Pharmaceuticals Inc.
  14.146.1 Amphocil
  14.146.2 Doxil
14.147 Serina Therapeutics Inc.
  14.147.1 POZ Technology
  14.147.2 Serina’s Pipeline
14.148 Serpin Pharma LLC
  14.148.1 SP16
14.149 Silence Therapeutics PLC
14.150 Silenseed Ltd.
  14.150.1 The LODER Platform
14.151 Sylentis SA
  14.151.1 Bamosiran
  14.151.2 SYL 1001
14.152 SoluBest Ltd.
  14.152.1 Solumer Technology
  14.152.2 Sepomer Technology
  14.152.3 Contromer
  14.152.4 Advanced Stage Products
  14.152.5 Fenofibrate
  14.152.6 Albendazole
  14.152.7 Resveratrol
  14.152.8 Testosterone undecanoate
14.153 Spark Therapeutics
14.154 Spheringenics Inc.
  14.154.1 Technology
14.155 Suda Ltd.
  14.155.1 Technology
  14.155.2 ZolpiMist: Insomnia
  14.155.3 ArTiMist: Malayria
  14.155.4 SUD-001: Migraine
  14.155.5 SUD-002: Nausea
  14.155.6 SUD-003: Erectile Dysfunction
  14.155.7 SUD-004: Pulmonary Arterial Hypertension
  14.155.8 SUD-005: Anxiety
14.156 Supratek Pharma Inc.
  14.156.1 Biotransport Technology
  14.156.2 CombiForm Toolbox
  14.156.3 Product Pipeline
14.157 Taiwan Liposome Co. Ltd.
  14.157.1 Technology
    14.157.1.1 Nano-Emulsion
    14.157.1.2 Polymeric Mycelle
    14.157.1.3 NanoX
    14.157.1.4 Immunoliposome
    14.157.1.5 BioSeizer
  14.157.2 Pipeline
    14.157.2.1 Doxisome
    14.157.2.2 Lipo-Dox
    14.157.2.3 Lipotecan
    14.157.2.4 TLC178
    14.157.2.5 AmBiL
    14.157.2.6 ProFlow
    14.157.2.7 ProDex
    14.157.2.8 TLC599
14.158 TheraSource LLC
  14.158.1 rhMFG-E8
  14.158.2 Ghrelin
  14.158.3 AM/AMBP-1
14.159 Transgene SA
14.160 Valeant Pharmaceuticals International Inc.
  14.160.1 Efudex
14.161 Vect-Horus S.A.S.
  14.161.1 Technology
  14.161.2 Vect-Horus’ Scientific Collaboration with Servier
  14.161.3 Vect-Horus’ Scientific Collaboration with Servier
14.162 Vectura Group plc
  14.162.1 PowderHale
  14.162.2 ParticleMax
  14.162.3 GyroHaler
  14.162.4 Akita Jet
  14.162.5 Akita Apixneb
  14.162.6 Fox
14.163 Vical Inc.
  14.163.1 Poloxamer Delivery System
  14.163.2 Vaxfectin Adjuvant
14.164 Voyager Therapeutics Inc.
14.165 WAVE Life Sciences Pvt. Ltd.
  14.165.1 Platform
14.166 Xel Pharmaceuticals
  14.166.1 Xel’s Proprietary Drug Delivery Technologies
  14.166.2 Transdermal Delivery System
  14.166.3 Topical Delivery System
  14.166.4 Implant Delivery Systems
  14.166.5 Oral Controlled Release
  14.166.6 Effervescent Tablet/Lozenge
  14.166.7 Cold Water Extraction
14.167 Xenetic Biosciences
  14.167.1 Technologies
    14.167.1.1 PolyXen
    14.167.1.2 OncoHist
14.168 Xigen SA
  14.168.1 Technology
14.169 Zealand Pharma AS
14.170 Zozano Pharma Corp.
  14.170.1 ZP-PTH
  14.170.2 Zozano’s Product Pipeline